Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.
NCT ID: NCT02859350
Last Updated: 2018-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
135 participants
INTERVENTIONAL
2016-11-30
2018-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants
NCT02613520
Regimen Optimization Trial of PfSPZ Vaccine in Equatorial Guinea
NCT03590340
Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated PfSPZ Vaccine in Equatoguinean Adults
NCT02418962
Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults
NCT02132299
PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States
NCT02773979
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The trial will consist of seven groups (Group 1a: younger adults, ages 18-35; Group 2: older adults, ages 36-65; Group 3: adolescents, ages 11-17; Group 4: older children, ages 6-10; Group 5: younger children, ages 1-5; Groups 6a/b: infants, ages 6 months - 11 months) of volunteers. Vaccination will begin in Group 1a (younger adults), with three doses of 2.7x10\^6 PfSPZ Vaccine given eight weeks apart by DVI. An eighth group (Group 1b: younger adults, ages 18- 35), will be uniquely immunized with the comparator vaccine PfSPZ Challenge given under chloroquine prophylaxis (PfSPZ-CVac approach), rather than with PfSPZ Vaccine. A single PfSPZ-CVac younger adult group (group 1b) is included to provide a direct comparison with PfSPZ Vaccine (group 1a) for the ability to protect against CHMI. Each of the first two groups (1a and 1b) will have 20 participants receiving either PfSPZ Vaccine or PfSPZ Challenge and 6 participants receiving NS placebo by DVI, with treatment allocation randomized and double-blind. Volunteers in Group 1b will receive vaccinations 8 weeks after the initial vaccination of Group 1a. Volunteers in Group 1 (younger adults) will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/- 7 days on each side) and will be followed for 8 weeks following CHMI.
Group 2 (older adults) will receive three doses of 2.7x10\^6 PfSPZ Vaccine. Group 2 will consist of 12 participants receiving PfSPZ Vaccine and 4 participants receiving NS placebo by DVI, given eight weeks apart. Group 3, 4, 5 and 6b will each have 12 participants receiving three doses of 1.8x10\^6 PfSPZ Vaccine and 4 participants receiving NS, also given eight weeks apart. Group 6a will consist of 3 volunteers who will receive a single dose of 9.0 x10\^5 PfSPZ Vaccine.
Sequential age groups will be staggered to allow assessment of safety and tolerability before further age de-escalation. To assure safety, vaccinations will start in younger adults and will progress to younger and older age groups using staggered start dates at approximately weekly intervals. Age escalation and initial age de-escalation will take place at the same time, hence Group 2 and 3 will be vaccinated at the same time. Progressively younger age groups will then be immunized. The decision to proceed with each of these steps will be made by the study team after a review of safety data from the previously vaccinated group(s). Three Safety Monitoring Committee (SMC) meetings are scheduled to review data prior to initiating the younger children and infant groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1a (PfSPZ Vaccine)
18-35 years; n= 20; 3 doses of 2.7x10\^6 PfSPZ Vaccine given eight weeks apart. Volunteers will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
PfSPZ Vaccine
Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
PfSPZ Challenge (for CHMI)
live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
Group 1a (normal saline)
18-35 years; n=6; 3 doses of normal saline given 8 weeks apart. Volunteers will receive CHMI between 10 and 14 weeks post last dose of NS (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
PfSPZ Challenge (for CHMI)
live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
Normal Saline
0.9% Sodium chloride
Group 1b (PfSPZ CVac)
18-35 years; n=20; 3 doses of 1.0x10\^5 PfSPZ Challenge given every four weeks. Group 1b will start 8 weeks after Group 1a. Volunteers in Group 1b will receive their first immunization after the loading dose of chloroquine has been administered. Volunteers will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
PfSPZ Challenge (for CHMI)
live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
PfSPZ Challenge (for PfSPZ-CVac)
live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge)
Group 1b (normal saline)
18-35 years; n=6; 3 doses of normal saline given 4 weeks apart. Group 1b will start 8 weeks after Group 1a. Volunteers will receive CHMI between 10 and 14 weeks post last dose of NS (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
PfSPZ Challenge (for CHMI)
live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
Normal Saline
0.9% Sodium chloride
Group 2 (PfSPZ Vaccine)
36-65 years; n=12; 3 doses of 2.7x10\^6 PfSPZ Vaccine given 8 weeks apart. Group 2 will start 3 weeks after Group 1a.
PfSPZ Vaccine
Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
Group 2 (normal saline)
36-65 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 2 will start 3 weeks after Group 1a.
Normal Saline
0.9% Sodium chloride
Group 3 (PfSPZ Vaccine)
11-17 years; n=12; 3 doses of 1.8x10\^6 PfSPZ Vaccine given 8 weeks apart. Group 3 will start 3 weeks after Group 1a.
PfSPZ Vaccine
Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
Group 3 (normal saline)
11-17 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 3 will start 3 weeks after Group 1a.
Normal Saline
0.9% Sodium chloride
Group 4 (PfSPZ Vaccine)
6-10 years; n=12; 3 doses of 1.8x10\^6 PfSPZ Vaccine given 8 weeks apart. Group 4 will start 4 weeks after Group 1a.
PfSPZ Vaccine
Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
Group 4 (normal saline)
6-10 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 4 will start 4 weeks after Group 1a.
Normal Saline
0.9% Sodium chloride
Group 5 (PfSPZ Vaccine)
1-5 years; n=12; 3 doses of 1.8x10\^6 PfSPZ Vaccine given 8 weeks apart. Group 5 will start 7 weeks after Group 1a.
PfSPZ Vaccine
Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
Group 5 (normal saline)
1-5 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 5 will start 7 weeks after Group 1a.
Normal Saline
0.9% Sodium chloride
Group 6a (PfSPZ Vaccine)
6-11 months; n=3; 1 dose of 9.0x10\^5 PfSPZ Vaccine. Group 6a will start 7 weeks after Group 1a.
PfSPZ Vaccine
Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
Group 6b (PfSPZ Vaccine)
6-11 months; n=12; 3 doses of 1.8x10\^6 PfSPZ Vaccine given 8 weeks apart. Group 6b will start 11 weeks after Group 1a.
PfSPZ Vaccine
Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
Group 6b (normal saline)
6-11 months; n=4; 3 doses of normal saline given 8 weeks apart. Group 6b will start 11 weeks after Group 1a.
Normal Saline
0.9% Sodium chloride
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PfSPZ Vaccine
Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
PfSPZ Challenge (for CHMI)
live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
Normal Saline
0.9% Sodium chloride
PfSPZ Challenge (for PfSPZ-CVac)
live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* From the age 6 months to 65 years
* Adults with a Body Mass Index (BMI) 18 to 30 Kg/m2; or adolescents, children and infants with Z-score of the selected indicator (\[weight-for-height\], \[(height and BMI) for age\]) category within ±2SD as detailed in protocol
* Long-term (at least one year) or permanent residence in the Baney district or Malabo city
* Agreement to release medical information and to inform the study doctor concerning contraindications for participation in the study
* Willingness to be attended to by a study clinician and take all necessary medications prescribed during study period
* Agreement to provide contact information of a third party household member or close friend to study team
* Agreement not to participate in another clinical trial during the study period
* Agreement not to donate blood during the study period
* Able and willing to complete the study visit schedule over the study follow up period, including the hospitalizations required for protocol compliance
* .Willingness to undergo HIV, hepatitis B (HBV) and hepatitis C (HCV) tests
* Volunteer (subjects 18 years of age and older) or the parent / guardian signing the informed consent (for subjects \<18 years of age) is able to demonstrate their understanding of the study by responding correctly to 10 out of 10 true/false statements (in a maximum of two attempts for those who failed to respond correctly to all true/false statements in the first attempt).
* Signed written informed consent, in accordance with local practice, provided by adult volunteers, parents or legal representatives and relevant assent for children participants as applicable.
* Free from malaria parasitemia by blood smear at enrollment and by PCR for group 1
* Has not been treated with any antimalarial medication for at least two weeks prior to the first immunization.
* Free from helminth infections (detected by microscopy) at enrollment.
* Female volunteers aged 9 years and above must be non-pregnant (as demonstrated by a negative urine pregnancy test), and provide consent/assent of their willingness to take protocol-defined measures not to become pregnant during the study and safety follow-up period.
Exclusion Criteria
* Participation in any other clinical study involving investigational medicinal products including investigational malaria drugs within 30 days prior to the onset of the study or during the study period
* History of arrhythmias or prolonged QT-interval or other cardiac disease, or clinically significant abnormalities in electrocardiogram (ECG) at screening
* Positive family history in a 1st or 2nd degree relative for cardiac disease at age \<50 years old
* A history of psychiatric disease
* Suffering from any chronic illness including; diabetes mellitus, cancer or HIV/AIDS
* Any confirmed or suspected immunosuppressive or immune-deficient condition, including asplenia
* History of drug or alcohol abuse interfering with normal social function
* The use of chronic immunosuppressive drugs or other immune modifying drugs within three months of study onset (inhaled and topical corticosteroids are allowed) and during the study period
* Any clinically significant deviation from the normal range in biochemistry or hematology blood tests or in urine analysis
* Positive HIV, hepatitis B virus or hepatitis C virus tests
* Volunteers who are have risk factors for tuberculosis and/or signs and symptoms of tuberculosis (TB), plus a positive tuberculin skin test (TST).
* Symptoms, physical signs and laboratory values suggestive of systemic disorders including renal, hepatic, blood, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, and other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers
* Any medical, social condition, or occupational reason that, in the judgment of the investigator, is a contraindication to protocol participation or impairs the volunteer's ability to give informed consent, increases the risk to the volunteer because of participation in the study, affects the ability of the volunteer to participate in the study or impairs the quality, consistency or interpretation of the study data
* History of non-febrile seizures or atypical febrile seizures
6 Months
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ifakara Health Institute
OTHER
Swiss Tropical & Public Health Institute
OTHER
Government of Equatorial Guinea
OTHER_GOV
Marathon Oil Corporation
INDUSTRY
Noble Oil Services
INDUSTRY
La Paz Medical Center, Malabo, Equatorial Guinea
UNKNOWN
Sanaria Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Salim Abdulla, MD, PHD
Role: STUDY_DIRECTOR
Ifakara Health Institute (IHI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
La Paz Medical Center
Malabo, , Equatorial Guinea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jongo SA, Urbano Nsue Ndong Nchama V, Church LWP, Olotu A, Manock SR, Schindler T, Mtoro A, Kc N, Devinsky O, Zan E, Hamad A, Nyakarungu E, Mpina M, Deal A, Bijeri JR, Ondo Mangue ME, Ntutumu Pasialo BE, Nguema GN, Rivas MR, Chemba M, Ramadhani KK, James ER, Stabler TC, Abebe Y, Riyahi P, Saverino ES, Sax J, Hosch S, Tumbo A, Gondwe L, Segura JL, Falla CC, Phiri WP, Hergott DEB, Garcia GA, Maas C, Murshedkar T, Billingsley PF, Tanner M, Ayekaba MO, Sim BKL, Daubenberger C, Richie TL, Abdulla S, Hoffman SL. Safety and Immunogenicity of Radiation-Attenuated PfSPZ Vaccine in Equatoguinean Infants, Children, and Adults. Am J Trop Med Hyg. 2023 May 9;109(1):138-146. doi: 10.4269/ajtmh.22-0773. Print 2023 Jul 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EGSPZV2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.